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INTRODUCTION:
Interleukin-6 (IL6) is an inflammatory cytokine that plays numerous roles in the tumor microenvironment influencing tumor cell proliferation, survival, migration and effects on stromal cells. Some of the effects of IL6 signaling, mediated through a specific receptor (IL6R), can have a positive or negative effect on tumor progression. In this study, we attempt to elucidate the pleiotropic effects of IL6 signaling in several models of ovarian cancer, with the ultimate aim of specifically targeting the protumor effects and hence reducing the mortality associated with this disease. To do this, we investigate the effects of both tumor cell and host stromal production and response to IL6R. We investigate the effects of the various IL6R isoforms in altering the progression of ovarian cancer. The goal is to specifically target the effects of IL6 signaling that facilitate ovarian tumor metastasis.
BODY:

Statement of Work Task 1. Identification of IL-6R isoforms in patient samples (Months 1 -12). (i) RNA isolation and real-time PCR analysis of patient samples
It is well known that IL6 expression in patients is associated with increasing stage of ovarian cancer. However, it was not clear whether the expression of IL6R, a necessary component of IL6 signaling, was also increased. We isolated RNA from non-tumor nearing ovaries and from patient ovarian cancer samples, and performed real-time PCR analysis on these samples. We found a dramatic upregulation of IL6R in advanced ovarian cancer samples compared with benign ovaries (Figure 1 , Rath et al., 2010 (1), Appendix 1). In addition, we confirmed increased IL6 expression in advanced cancers. These findings indicate the relevance of IL6 signaling in the ovarian tumor microenvironment.
In our further analyses, we used Q-PCR primers specific for the full length and differentiallyspliced isoforms of IL6R to identify which isoform was more prevalent in ovarian tumors. Somewhat surprisingly, we found that both malignant tumor samples from patients and ovarian carcinoma cell lines expressed greater amounts of the differentially spliced isoform than any other tissue studied to date, including liver, immune cells or benign ovaries ( Figure 2 , (1)). Liver and immune cells are known to be the major sources of IL6R in the obdy. The implications of this finding are that tumors contribute additional IL6R to their microenvironment in the form of the less common differentially-spliced variant.
(ii) and (iii) Protein analyses including immunohistochemistry and in situ hybridization of IL6R isoforms in patient samples.
We have performed sectioning and immunohistochemistry on patient ovarian cancer samples to localize IL6R expression within the tumor. Towards this end, we have demonstrated that IL6R was only expressed in the surface epithelium of benign ovaries and absent from the stroma, the major constituent of non-tumor-bearing ovaries. In ovaries bearing epithelial malignancies, we showed that IL6R once again localized to the epithelium and not the tumor stroma ( Figure 1C and D, Rath etal., 2010) . Given that the epithelial tumor cells constitute most of the ovarian tissue in advanced stage tumors, IL6R expression was therefore greatly increased in malignant ovarian samples, consistent with the RNA data obtained earlier. The successful localization of IL6R expression obviated the need for in situ hybridization analysis.
We had proposed the usage of an antibody (2F3) reported to specifically identify the differentially-spliced form of IL6R (2) . We obtained this antibody from the reporting investigator and performed rigorous testing of the specificity of this antibody. Unfortunately, we could not demonstrate specificity of this antibody for the differentially-spliced isoform of IL6R. To the best of our knowledge, no other antibody has reported to fulfill this purpose so this confirmatory study has not been continued at this point. However, combining the abovementioned results, we have obtained sufficient data to demonstrate that IL6R expression in tumors localizes to the epithelial ovarian tumor cells, and that it is the differentially-spliced isoform that is greatly upregulated.
Task 2. In vivo experiments to determine functions of IL-6R isoforms and tumor:stroma relationship (Months 4-24) (i)
Increase mouse breeding and genotyping to ensure sufficient numbers of mice for experiments.
Mouse breeding and genotyping have been sufficiently increased to provide adequate numbers of mice in the following colonies: wild-type, IL6 (ii) Implant KD and control tumor cells into the ovaries of groups of 10 SCID or C57Bl6 mice followed by monitoring and necropsy.
Towards this end we have generated ovarian carcinoma cell lines overexpressing IL6R, with knockdown of IL6R, and control vector-expressing lines for each. These cells have been implanted into the ovaries of mice. We have made the novel finding that tumor cell expression of IL6R greatly enhances the earliest metastases of ovarian cancer to the omentum. It has previously been demonstrated that the omentum is among the earliest sites in which ovarian metastases are observed and is a preferred site for metastases (4) . We have previously shown similar metastatic dissemination patterns in mouse models (5) . We are now undertaking detailed studies to identify which IL6 downstream signaling pathways are required for this effect and which of the downstream candidate molecules we have identified are involved. This study will provide a target for blocking the protumor effects of IL6R.
(iii) Implant tumor cells into groups of 10 IL-6R-/-, LysMCre IL-6R
-/-, AlbCre IL-6R
-/-and wild type mice followed by monitoring and necropsy. 6 This experiment has been performed and indicates that not only is host IL6R influential in tumor progression, but that myeloid sources (macrophages) are more directly involved than hepatic IL6R. Current experiments are underway to determine whether myeloid cells in the omentum, peritoneum or periphery are more relevant. These experiments provide a rationale for targeting host IL6R isoforms. Further, our xenograft studies have shown that host IL6R is another means by which IL6R levels are increased in the ovarian tumor microenvironment.
(iv) Reconstitution (soluble IL-6R and gp130) in IL-6-/-and wild type mice; tumor implantation, monitoring and necropsy.
Mice have been generated for this experiment and soluble recombinant proteins have been purchased. Experiments will commence shortly.
(v) Histologic and molecular analysis of mouse tissues, as they become available.
Tissues from the completed mouse studies indicated above have been processed, embedded and sectioned for H&E and immunohistochemical analyses. Analyses to-date have localized tumor cells overexpressing IL6R to myeloid cells in the omentum. The intricate association between these cell types appears to be highly relevant to early metastases of ovarian cancer and is being further explored.
(vi) Preparation of manuscripts.
This task is currently underway to publish the data on the mouse studies of tumor:stromal relationship. The final study of reconstituting soluble gp130 and IL6R will be prepared for publication when the results become available.
KEY RESEARCH ACCOMPLISHMENTS:
Identification of IL6R in ovarian tumor microenvironment Demonstration that differentially-spliced isoform of IL6R is prominent in ovarian cancer Host expression of IL6R contributes to the total amount of IL6R present in the tumor microenviroment Finding that IL6R expression enhances the earliest metastases of ovarian cancer Myeloid cell expression of IL6R is critical to influencing early tumor adhesion to the omentum O varian cancer is the most deadly of the gynecological malignancies. 1 Most gynecologic oncologists initially treat the disease with debulking surgery, followed by adjuvant chemotherapy with platinum and taxane agents. After an initial response to chemotherapy, the cancer will recur in the majority of patients but with chemoresistant properties. The efficacy of second-line and salvage therapies for patients who fail initial surgical and medical therapy is limited at best. A greater understanding of the mechanisms by which ovarian cancers metastasize and develop chemoresistance is essential for reducing the high mortality associated with these malignancies. Interleukin-6 (IL-6) is an important proinflammatory cytokine that is frequently up-regulated in acute and chronic inflammatory conditions, including many cancers (reviewed elsewhere 2 ). IL-6 signaling occurs through a hexameric complex of IL-6, a specific ␣ receptor (IL6R; glycoprotein [gp]80), and a shared ␤-signaling receptor (gp130). 3 Dimerization of gp130 leads to activation of Janus tyrosine kinases and subsequent translocation of signal transducer and activator of transcription (Stat) transcription factors. 4 Stat3 is the major Stat induced by IL-6 signaling, and its nuclear translocation induces a transcriptional program resulting in inflammation, cell survival, or differentiation, depending on the cellular context. 5, 6 In addition to membrane-bound IL6R, several soluble isoforms also exist. 7 Expression of both membrane-bound and soluble forms of IL6R are largely restricted to hepatocytes and immune cells, and therefore, signaling through membrane-bound IL6R is restricted to these cells. However, the soluble isoforms of IL6R are excreted from these cells types and unexpectedly function as agonists for IL6R signaling and hence allow IL6R-mediated signaling in cells that do not express IL6R. This occurs through initial binding of IL-6 to soluble extracellular IL6R and subsequent binding of this complex to the membranebound signaling receptor, gp130.
This binding results in dimerization of gp130, which, in turn, leads to stat3 activation that occurs in a similar fashion to that induced by membrane-bound IL6R. Because gp130 is ubiquitously expressed, the potential to respond to IL-6 is conferred on all cells in the presence of soluble IL6R. This process, known as transsignaling, 8 has been found to be important in multiple disease states including rheumatoid arthritis, asthma, inflammatory bowel disease, and colon cancer. [9] [10] [11] It has been shown that many of the inflammatory functions of IL-6 signaling can be prevented by inhibiting the soluble isoform of IL6R with a solu-ble form of gp130. 12 Therefore, the soluble isoform plays important roles in inflammatory contexts by allowing a heightened response to IL-6 in all cell types at the site of inflammatory challenge.
Soluble IL6R can be generated by 2 distinct processes: differential splicing and proteolytic cleavage. [13] [14] [15] The differentially spliced isoform lacks a transmembrane domain and is secreted as a soluble, functional receptor. 16 The proteolytic enzymes responsible for cleavage of full-length IL6R are a disintegrin and metalloprotease domain (ADAM)-17, also known as tumor necrosis factor alpha-converting enzyme and to a lesser extent, ADAM10. [17] [18] [19] These sheddases cleave full-length IL6R in a membrane proximal site to release a soluble, functional receptor. A study of IL-6 signaling in an angiotensin-induced cardiac model suggested that the 2 forms of soluble IL6R may have different functions leading to either hypertrophy or hypertension. 20 It is well established that IL-6 is upregulated in both the serum and ascites of ovarian cancer patients and is associated with disease progression. [21] [22] [23] IL-6 has also been implicated in chemotherapeutic resistance in ovarian cancer cell lines and in patients with ovarian cancer. 22, 24, 25 However, the status of IL6R expression in ovarian cancer has not been adequately addressed to date. One study reports increased expression of soluble IL6R in the sera of patients in the early stages of various tumor types, but specific data for ovarian cancer were not available. 26 Despite the importance of the soluble isoforms of IL6R in inflammation, there has not been a characterization of these isoforms in ovarian cancer.
Given that we have previously shown that inflammation drives the spread of ovarian tumors in murine models, 27 a thorough evaluation of inflammatory IL6R isoforms in the tumor microenvironment is needed. Here we describe the increased expression of IL-6, total IL6R, differentially spliced IL6R, ADAM10, and ADAM17 in ovarian tumors. Furthermore, we show that both tumor and host cells contribute to soluble IL6R expression in the tumor environment.
MATERIALS AND METHODS
Patient tissue collection and cell lines
Tissue samples from malignant and nonmalignant ovaries were collected from patients undergoing routine gynecologic procedures at the University Hospital and the Christ Hospital in Cincinnati, OH (Table 1) . Normal ovarian tissue was collected from patients 1-16. Malignant tissue collected from patients 17-27 were from primary ovarian epithelial carcinomas. Tissues were immediately snap frozen in liquid nitrogen at the time of surgery and stored at Ϫ80°C until analysis. Human ES-2 and SKOV3, clear cell and serous papillary ovarian carcinoma cell lines, respectively, were obtained from American Type Culture Collection (Manassas, VA). Cells were maintained in Dulbecco's Modified Eagles media with 10% 27 Groups of mice (n ϭ 6) were administered acetyl salicylic acid (ASA; 100 mg/kg; Sigma, St Louis, MO), phosphate-buffered saline, or thioglycolate (0.5 mL of a 3% solution; Fluka, Buchs, Switzerland) by twice-weekly intraperitoneal injection. Additional mice without tumors were administered ASA, saline, or thioglycolate. Peritoneal lavage with phosphate-buffered saline was performed on anesthetized mice. Lavage fluid was centrifuged and stored at Ϫ80°C until analysis. Guidelines for the care and use of laboratory animals approved by the University of Cincinnati Institutional Animal Care and Use Committee were followed.
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
Ribonucleic acid (RNA) was extracted from patient tissue samples with the RNeasy lipid kit (Qiagen, Valencia, CA) and quantified with a spectrophotometer (Nanodrop, Wilmington, DE). Reverse transcription was performed with the Thermoscript II kit (Invitrogen, Carlsbad, CA). Real-time polymerase chain reaction (PCR) was performed with primers specific for IL-6, both isoforms of IL6R (total IL6R), fulllength IL6R (variant 1), differentially spliced IL6R (variant 2), ADAM10, and ADAM17 (Table 2 ) with a Realplex Mastercycler (Eppendorf, Netheler, Germany). Primer specificity was confirmed by checking product sizes on an agarose gel and performing a melt-curve analysis on each run. Gene expression was normalized against the human L32 housekeeping gene, as previously described.
28
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded samples of both benign and malignant ovarian tissue to detect IL6R. Briefly, samples were deparaffinized, and antigen retrieval was performed in citrate buffer (10 mM with 0.05% Tween 20, pH 6.0) for 10 minutes at 95°C. Slides were incubated overnight with rabbit antihuman IL6R (sc-661; detects both isoforms) at a dilution of 1:400 at 4°C, followed by biotinylated goat antirabbit immunoglobulin G (1:200).
ABC Elite kit (Vector, Burlingame, CA) and 3,3 diaminobenzidine substrate (Sigma) were used in the detection, followed by hematoxylin counterstain.
IL6R ELISA
Peritoneal lavage fluid from mice was analyzed by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions, to assess expression of human and murine soluble IL6R. Cross-reactivity between human 
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and mouse IL6R is negligible with the use of these species-specific IL6R ELISA kits. The enzymatic reactions were detected at 570 nm and subtracted from background at 450 nm with a spectrophotometric plate reader.
Statistical methods
Data are represented as mean Ϯ SEM were analyzed by the Mann-Whitney U test.
RESULTS
Twenty-seven patient samples were collected: 16 with benign ovarian pathology and 11 with ovarian carcinoma (Table  1) . Patient age ranges were not significantly different for benign ovary samples (39 -71 years; average, 49.1 years) and malignant tumor samples (36 -77 years; median, 59.5 years). All tumors were papillary serous and predominantly stage IIIC according to International Federation of Gynecology and Obstetrics classification.
To quantify the production of IL-6 and IL6R in benign ovaries and malignant ovarian tumors, we assessed RNA expression by real-time PCR. We found dramatic up-regulation of IL-6 in malignant ovaries compared with benign ovaries ( Figure 1 , A), consistent with previous reports. [21] [22] [23] Expression of IL6R was also found to be up-regulated in ovarian malignancies (Figure 1, B) .
We next sought to identify, by immunohistochemistry, the cell types responsible for IL6R expression in normal and malignant ovarian tissue. IL6R was predominantly expressed in the epithelium of normal ovaries and only minimally in the stroma (Figure 1, C) . In serous papillary tumors, IL6R expression was strong in tumor cells and negligible in the tumor stroma (Figure 1, D) . Ovarian IL6R expression was therefore a function of both normal and malignant epithelium.
Given the markedly higher proportion of cells expressing IL6R in malignant ovaries, it would be reasonable to expect that the difference in messenger RNA (mRNA) expression levels between normal and malignant tissue would be even greater. This apparent underrepresentation by quantitative PCR could be due to differences in transcriptional or translational efficiencies or to soluble IL6R protein localizing to malignant ovaries despite being produced elsewhere.
Soluble IL6R is known to be important in many inflammatory contexts. 9 To determine whether malignant ovarian tumors were predominantly expressing the full-length (variant 1) or the differentially spliced isoform that lacks the transmembrane domain (variant 2), we used real-time PCR with primers specific for each isoform. Interestingly, we found that the ratio of variant 2 relative to variant 1 was higher in malignant tumor samples than in a human monocytic cell line, normal liver, or benign ovarian samples ( Figure 2 ).
IL6R expression is largely restricted to hepatocytes and immune cells (and some tumor cells); however, expression of soluble IL6R at sites of inflammation, tumors, or both allows IL-6 signaling in other cell types. To determine whether soluble host IL6R expression contributes to the increase in IL6R in the context of an ovarian cancer in vivo, we used a murine xenograft model. Human ovarian carcinoma cell lines were implanted orthotopically into the ovaries of immunecompromised SCID mice.
We implanted cell lines positive (SKOV3) and negative (ES2) for IL6R expression. The rate of tumor formation by SKOV3 cells implanted in the ovary was approximately 50%. Human IL6R was detected in mice in which SKOV3 cell tumors developed but not in ovaries in which tumors did not develop or in ES-2 cell-derived tumors (100% take rate), indicating the specificity of the ELISA (Figure 3 , A). Mice that developed ovarian carcinoma had elevated levels of host (mouse) peritoneal soluble IL6R when compared with mice that did not develop carcinoma (Figure 3 , B). Tumor 
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development was identified by gross analysis at necropsy and confirmed by histological analysis (data not shown).
To determine the role of inflammation in host IL6R expression in ovarian tumors, mice were treated with ASA to suppress inflammation, thioglycollate to increase inflammation, or phosphatebuffered saline (vehicle control) during tumor progression. Soluble levels of mouse IL6R were highest in mice treated with thioglycollate and lowest in mice treated with ASA ( Figure 4, A) .
This pattern of expression closely paralleled that of tumor burden in the mice, as assessed by ascite development and percentage of the diaphragm covered with tumor ( Figure 4 , B and inset). Mice that received inflammation-modulating drugs but that were not implanted with tumor cells expressed only baseline levels of IL6R (Figure 4 , A). These data indicate that the increased expression of host soluble IL6R expression was a direct result of the presence of tumor in the peritoneum but was also influenced by the degree of inflammation.
Finally, we evaluated the expression of the 2 known physiological sheddases for full-length IL6R, ADAM17, and ADAM10. We found that the expression of ADAM17 and ADAM10 was increased in malignant ovaries, as compared with benign tissue ( Figure 5 ). The dramatic local increase in expression of these proteases in malignant ovarian tumors provides another mechanism by which soluble IL6R can be generated in the tumor microenvironment.
COMMENT
IL6R plays numerous roles in inflammatory responses and tumor progression. 2, 29 In this study, we found that IL6R is expressed in normal and malignant epithelium. We have demonstrated several mechanisms by which increased levels of soluble IL6R occur in the tumor microenvironment, including increased expression of a differentially spliced soluble isoform, up-regulation of sheddases for the membrane-bound form, and increased host expression of soluble IL6R. The increase of IL6R facilitates enhanced responsiveness to IL-6 in ovarian malig- 
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nancies, contributing to increased phosphorylation of Stat3 and up-regulation of cell-survival pathways. 24, 30, 31 With no inherent kinase activity, IL6R functions to recognize its specific ligand and to induce dimerization of gp130, the signaling component of the complex. IL6R carries out this role in either soluble or membrane-bound forms; thus, the soluble receptor is effectively an agonist for IL-6 signaling. In fact, blocking only the soluble form of IL6R with exogenous soluble gp130 prevents many, if not all, of the known functions of IL-6 in inflammatory contexts. 11, 12 In the current study, we demonstrate that tumor cells preferentially express a differentially spliced isoform of IL-6R that lacks the transmembrane domain. Expression of this soluble differentially spliced isoform has previously been reported in a subset of monocytes and in several carcinoma cell lines. 32 In addition, our findings suggest that soluble IL6R may also be generated in malignant ovaries by cleavage of the membranebound form by increased levels of ADAM10 and ADAM17 proteases. Production of soluble IL6R in ovarian tumor cells may serve to increase IL-6 responsiveness in surrounding tumor cells, stromal cells, or peritoneal mesothelial cells.
Little has been learned about the contribution of the stroma to the expression of IL6R within the context of a tumor, owing to the difficulty in identifying the source of soluble IL6R. Here we have utilized a xenograft model and species-specific ELISAs to allow the distinction between tumor (human) and host (murine) IL6R.
Our data show that, in addition to tumor cell production of IL6R, host cells make a significant contribution to the increased expression of soluble IL6R in the peritoneal environment and that IL6R levels reflect the degree of peritoneal inflammation. It was not possible to determine whether host-derived IL6R is the differentially spliced isoform because this variant is lacking in mice. It is tempting to speculate that immune cells are a predominant source of host IL6R because they are abundant in the ascites 
IL6R expression is influenced by mediators of inflammation during tumor progression
A, Suppressing inflammation with ASA during tumor progression significantly reduced host (mouse) IL6R expression (P Ͻ .05). Augmenting inflammation with thioglycollate showed a trend toward increased mouse IL6R expression. B, The pattern of IL6R expression during inflammation modulation closely resembled that of ascites production (inset) and tumor burden. Asterisk indicates P Ͻ .05. 
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fluid [33] [34] [35] and are known to be a source of shed IL6R in inflammatory contexts. 36 Given the importance of IL-6 signaling in inflammation, tumor growth, differentiation, and chemoresistance, the identification of IL6R isoforms in malignant ovarian tumors may provide novel therapeutic opportunities. Here we show that expression of soluble isoforms of IL6R is increased by multiple mechanisms, including preferential production of a differentially spliced variant, increased production of sheddases for membrane-bound IL6R, and up-regulation of host inflammation-induced soluble IL6R in the tumor microenvironment. Together these data suggest that trans-signaling through IL6R is a feature of ovarian tumors and that targeting IL6R may provide a novel treatment to decrease the morbidity and mortality of this disease. IL-6 modulates immune responses and is essential for timely wound healing. As the functions mediated by IL-6 require binding to its specific receptor, IL-6Ra, it was expected that mice lacking IL-6Ra would have the same phenotype as IL-6-deficient mice. However, although IL-6Ra-deficient mice share many of the inflammatory deficits seen in IL-6-deficient mice, they do not display the delay in wound healing. Surprisingly, mice with a combined deficit of IL-6 and IL-6Ra, or IL-6-deficient mice treated with an IL-6Ra-blocking Ab, showed improved wound healing relative to mice with IL-6 deficiency, indicating that the absence of the receptor contributed to the restoration of timely wound healing, rather than promiscuity of IL-6 with an alternate receptor. Wounds in mice lacking IL-6 showed delays in macrophage infiltration, fibrin clearance, and wound contraction that were not seen in mice lacking IL-6Ra alone and were greatly reduced in mice with a combined deficit of IL-6 and IL-6Ra. MAPK activationloop phosphorylation was elevated in wounds of IL-6Ra-deficient mice, and treatment of wounds in these mice with the MEK inhibitor U0126 resulted in a delay in wound healing suggesting that aberrant ERK activation may contribute to improved healing. These findings underscore a deeper complexity for IL-6Ra function in inflammation than has been recognized previously. The Journal of Immunology, 2010, 184: 000-000.
I nterleukin 6 is a pleiotropic cytokine with roles in generating acute phase responses, inflammation, and lymphocyte differentiation. Numerous cell types produce IL-6, especially at sites of inflammation. IL-6 functions are mediated by binding to its specific receptor, IL-6Ra (gp80 and CD126). IL-6Ra is the only known receptor for IL-6, and its expression is predominantly restricted to hepatocytes and immune cells. Recently, ciliary neurotrophic factor (CNTF) and IL-27, two other members of the IL-6 family, have been demonstrated to bind IL-6Ra in vitro but with lower affinity than IL-6, and thus, the in vivo relevance of these findings remains unclear (1, 2). IL-6 engagement of IL-6Ra induces homodimerization of the ubiquitously expressed, common IL-6 family signaling receptor gp130 (IL-6 signaling transducer). Mammalian IL-6, however, cannot directly engage gp130 in the absence of IL-6Ra (3).
IL-6Ra contains an extracellular Ig-like domain, a cytokine receptor homology module, a transmembrane domain, and a nonsignaling intracellular domain. The cytokine receptor homology module is made up of two fibronectin type III domains and is responsible for recognition and binding of IL-6 and gp130 (reviewed in Ref. 4 ). Typical for a cytokine receptor, IL-6Ra does not possess kinase activity. Ligand-bound IL-6Ra induces dimerization of gp130 (5). The Janus family kinases, JAK1, JAK2, and TYK2, are constitutively associated with the cytoplasmic tail of gp130 and phosphorylate gp130 dimers (6, 7). The transcription factors Stat3 and, to a lesser extent, Stat1 dock at any of four C-terminal tyrosines on gp130 (8, 9) . JAKs phosphorylate the Stat proteins inducing Stat dimerization, translocation to the nucleus, and transcription of genes with IL-6-responsive elements (10). IL-6-induced Stat3 activation is negatively regulated by suppressor of cytokine signaling 3 and Src homology region 2 domain-containing phosphatase 2 binding to a membraneproximal gp130 phospho-tyrosine residue (Y759), resulting in Ras activation and ERK signaling (11) (12) (13) . Both Stat3 and Erk activation result in cell proliferation, survival, differentiation, and inflammation, and both are frequently upregulated in tumors.
IL-6 signaling can also occur through a soluble form of the receptor that can bind IL-6 and subsequently induce gp130 dimerization (3). This process is known as trans-signaling and allows cells that do not express IL-6Ra to respond to IL-6 (14) . Soluble forms of IL-6Ra occur as the result of either of two distinct processes: alternative splicing or proteolytic cleavage (15) (16) (17) . The importance of each isoform in physiologic processes is not clearly understood. It is known from mice overexpressing human soluble IL-6Ra that the soluble isoform plays a role in sensitizing cells to IL-6 signaling and prolonging IL-6 half-life (18) . Inhibition of the soluble form of IL-6Ra in vivo is sufficient to block many of the known functions of IL-6 signaling, such as modulation of the inflammatory response (19, 20) . Neutrophil infiltration and apoptosis are early events in the inflammatory response that trigger IL-6Ra shedding and subsequent monocyte infiltration (19) (20) (21) (22) . Despite high expression of membrane-bound IL-6Ra, human osteoblasts are unable to respond to IL-6 unless the receptor is cleaved to produce the soluble form (23). It has not been well established whether any nonredundant function exists for the membrane-bound form of IL-6Ra.
IL-6-deficient (Il6 2/2 ) mice were generated ∼15 y ago (24, 25) .
Their multiple phenotypic abnormalities are not surprising, because of the pleiotropic functions ascribed to IL-6. Although Il6 2/2 mice have no apparent developmental abnormalities, they have an impaired capacity to mount immune responses to several pathogens and to generate acute-phase responses (24) . In addition, they have reduced capacity for liver regeneration and develop age-related obesity (26, 27) . Il6 2/2 mice display resistance to experimental autoimmune conditions, such as encephalitis, and protection against bone loss after ovariectomy (25, 28) . Studies using experimental tumor models in Il6 2/2 mice have reported both tumor-protective and tumor-promoting effects for IL-6, depending on the tumor model used (29) (30) (31) . A better understanding of the functions of IL-6 and its receptor in different contexts may provide opportunities for more effective manipulation of IL-6 signaling in the treatment of inflammation and cancer. Il6 2/2 mice display significant defects in wound healing. Wound healing is a tightly regulated process in which platelets and fibrin immediately fill the wound bed with an insoluble clot, and significant neutrophil immigration occurs shortly thereafter (reviewed in Ref. 32 ). Re-epithelialization proceeds by adjacent keratinocyte proliferation and migration over the wound area. Neutrophils in wounds are important for microbe neutralization, but their absence from sterile wounds does not delay healing (33, 34) . Monocyte/macrophages are subsequently recruited and play roles in the clearance of debris and the provision of growth and angiogenic factors. Macrophages in wounds typically express markers indicating alternate activation pathways with functions in tissue remodeling and angiogenesis, rather than classically activated macrophages that function to kill pathogens. Wounds in mice with inhibited macrophage function display excess fibrin and cellular debris and heal more slowly than those in untreated mice (35) . Wound healing is delayed in Il6 2/2 mice as a result of impaired re-epithelialization, angiogenesis, and macrophage infiltration (36, 37) . In this paper, we report on mice with complete and conditional deficiencies of IL-6Ra, which were generated to better understand the relationship between soluble and membrane-bound receptor and to identify any phenotypic discrepancies that may exist, as compared with Il6 2/2 mice. Although IL-6 and IL-6Ra are believed to be exclusive and essential components of IL-6 signaling in vivo, we report both similarities and differences between the phenotypes of Il6 2/2 and Il6ra 2/2 mice. These studies indicate an unanticipated compensatory improvement in wound healing in Il6ra 2/2 mice but not in Il6 2/2 mice, which suggests a greater complexity in IL-6Ra function than was previously appreciated.
Materials and Methods
Generation of Il6ra-knockout mice IL-6ra-deficient mice were generated by the insertion of a targeting vector into the IL-6ra genomic locus. The targeting vector included the selection cassette loxP-frt-pMC1neopA-frt in which the neo gene is flanked by frt sites. Murine IL-6ra exons 4, 5, and 6 were inserted between the loxP sequences. The construct was introduced into embryonic stem (ES) cells on a C57BL/6 background for homologous recombination. To prevent changes in the level of gene expression in mice carrying the floxed allele, the resulting loxP sites of the recombined allele were located in nonconserved intronic sequences known to share no sequence conservation between mouse and human and to be devoid of transcription factor binding sites. Recombined ES cell clones were identified by PCR, and a successful single insertion was confirmed by Southern blot analysis. Blastocysts containing ES cells with the floxed allele were implanted, and germline mice were bred with EIIa-cre mice on a C57BL/6 background, resulting in the deletion of IL-6ra exons 4, 5, and 6 (the cytokine receptor binding module) and the Neo cassette. Further breeding with C57BL/6 mice was carried out to remove the Cre construct, and mice were then bred to homozygosity for the deleted IL-6ra allele. Genotypes were confirmed by PCR analysis and Southern blotting. Studies included in this paper have been reviewed and approved by the University of Cincinnati Institutional Animal Care and Use Committee.
Southern blot analysis
Genomic DNA was prepared by phenol/chloroform extraction and digested overnight with restriction enzymes. Samples were loaded onto a 0.8% agarose gel in tris-acetate EDTA buffer and electrophoresed. The gel was stained with ethidium bromide for 10 min in tris-acetate EDTA buffer, imaged by UV, and then transferred overnight in 203 SSC onto a positively charged nylon membrane (Roche, Basel, Switzerland). Digoxigenin (DIG)-labeled probes were prepared using the PCR DIG Probe Synthesis Kit (Roche), according to the manufacturer's instructions. The membrane was hybridized with 50 ng/ml DIG-labeled probe, followed by chemiluminescent detection with anti-DIG alkaline phosphatase Ab and CSPD substrate.
Generation and maintenance of mice with conditional expression of IL-6Ra
Mice with a floxed allele of IL-6ra (Il6ra 
Harvesting of normal and inflammatory-challenged tissues
Spleen, liver, and lung tissues were collected from euthanized mice for analysis. Plasma was prepared from EDTA-treated blood collected from the retro-orbital plexus. Hepatocytes were prepared from anesthetized mice by in situ liver perfusion and Percoll gradient separation, as described previously (41) . Thioglycolate-elicited macrophages and granulocytes were collected by peritoneal lavage 24 or 48 h after i.p. injection of 3% thioglycolate broth. Cells were incubated on plastic for 1 h to enrich for adherent macrophages. Acute-phase responses were assessed in plasma and livers collected from mice given a s.c. injection of 100 ml turpentine at various intervals prior to sacrifice.
Air-pouch experiments were performed as described previously (20) . Briefly, mice were injected s.c. in the center of the back with 6 and 4 ml sterile air at days 26 and 23, respectively, to create an air pouch. Inflammation was elicited at day 0 by injecting 1 ml 1% carrageenan (SigmaAldrich) in PBS into the air pouch. Lavage was performed at days 3 and 7 after carrageenan administration. Lavage fluid was spun onto slides with a cytospin (Thermo Shandon, Pittsburgh, PA) and stained with Kwik-Diff (Thermo Shandon). Differential cell counts were performed by a hematologist (C.A.M.) on three to four microscope fields per sample.
Full-thickness excisional wounds were prepared on shaved dorsal skin by 4-mm-punch biopsy (small wounds; Acuderm, Fort Lauderdale, FL) or with a fine-scissor cutting around a 1-cm 2 template (large wounds). Mice were housed individually, and wounds were left undressed. Wounds were photographed and examined daily, and the percentage of wound closure was assessed as the size of the remaining wound area relative to the original template. Wounds were collected after 1, 2, 5, 8, and 11 d for analysis. For MEK inhibition, wounds were treated daily with topical U0126 (10 mg dissolved in 25 ml DMSO; Selleck Chemicals, Houston, TX) or vehicle alone. In other experiments, mice were given daily peritoneal injections of Abs specific for mouse IL-6Ra (500 mg/mouse; BioExpress, West Lebanon, NH), mouse gp130 (7.5 mg/mouse; eBioscience, San Diego, CA), mouse IL-27/p28 (37 mg/mouse; Shenandoah Biotech, Warwick, PA), or rat IgG (Sigma-Aldrich) diluted to a similar concentration in PBS.
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Real-time PCR analysis RNA from WT and Il6ra 2/2 mice was isolated using the Nucleospin II Kit (Macherey-Nagel, Bethlehem, PA). One microgram of mRNA was reverse transcribed with the Thermoscript II Kit (Invitrogen, Carlsbad, CA). Twenty nanograms of cDNAwas used for subsequent PCR analysis. Quantitative PCR was performed using the Realplex Mastercycler (Eppendorf) and the following primers: L32 (Rpl32) 59-CTTAGAGGACACGTTGTGAG-CAATC-39 and 59-GCTGTGCTGCTCTTTCTACAATGGCTTTT-39; haptoglobin, 59-TATGGATGCCAAAGGCAGCTTTCC-39 and 59-TCGCTGTG-GTTCAGGAAGAGGTTT-39; serum amyloid A (SAA), 59-AGAGGAC-ATGAGGACACCATTGCT-39 and 59-AGGACGCTCAGTATTTGTCAGG-CA-39; and fibrinogen, 59-GATGAACAAATGTCACGCAGGCCA-39 and 59-GCCCAAATAATGCCGTCGTCGAAA-39. Each analysis was repeated at least twice to ensure reproducibility. To ensure specificity, real-time melt curves were analyzed, and band sizes were checked on agarose gels. Values were normalized against murine L32, housekeeping gene.
Western blotting and ELISA
Protein lysates were prepared from liver and spleen tissue and quantified by protein assay (Bio-Rad DC; Bio-Rad, Hercules, CA) for Western blotting. Reduced samples were electrophoresed on 8% polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). Membranes were blocked in 5% milk for 1 h. Primary Ab dilutions were applied at 4˚C overnight at the following dilutions: rabbit anti-mouse IL-6Ra IgG 
Histology and immunohistochemistry
Wound tissues were collected into Glyofixx fixative (Thermo Shandon) at necropsy and processed into paraffin. A separate group of wounds was fixed in zinc fixative (BD Biosciences, San Jose, CA) for CD31 immunostaining. 4 mm sections were prepared and routinely stained with H&E. Reepithelialization was assessed by measuring the percentage of the wound area covered with keratinocytes. Immunohistochemistry was performed on dewaxed tissues after Ag retrieval by heating in citrate buffer or EDTA (F4/80). Sections were blocked with 10% serum, 5% BSA in TBS. Primary Abs were used at the following dilutions: F4/80 (1/400; eBioscience), CD31 (BD Biosciences), fibrinogen [1/1000 (42)], and arginase I (1/100; BD Biosciences). Arginase staining was performed with the Mouse-onMouse Blocking kit (Vector Laboratories, Burlingame, CA). Endogenous peroxidase was blocked prior to adding biotinylated secondary Abs (1/200; Vector Laboratories). ABC Elite kit (Vector Laboratories) and diaminobenzidine (Sigma-Aldrich), VectorRed (Vector Laboratories), or Fast Red (Sigma-Aldrich) substrates were used. Morphometry was performed by investigators unaware of the genotypes of the mice. Vascular density was assessed by counting luminal structures in three high-power fields per wound. Macrophages were quantified by measuring the percentage of two randomly selected high-power fields within the wound area that were positive for the substrate (VectorRed) above a predetermined threshold (ImageJ software). Fibrin staining was assessed by a pathologist unaware of the mouse genotypes.
Statistics
Statistics were performed by the Mann-Whitney U test for pairwise comparisons or the Kruskall-Wallis test for multiple comparisons. Data are expressed as average 6 SEM.
Results
Generation of Il6ra
2/2 mice
Mice with a floxed allele of IL-6ra (Il6ra fl/+ ) were generated by homologous recombination with a vector containing LoxP sites around exons 4-6 and a neomycin cassette (Fig. 1A) . Il6ra fl/+ mice were crossed with EIIa-Cre mice, and the offspring were interbred to obtain mice with a complete deficiency of IL-6Ra (EIIa-Cre +/2 / IL-6Ra 2/2 ) (Fig. 1A) . Southern blotting indicated an absence of the WT 11-kb genomic DNA fragment and the presence of the predicted 9-kb excised allele in mice homozygous for the floxed allele (Fig. 1B) . Subsequent breeding to remove the Crerecombinase gene was performed. The absence of mRNA for IL-6ra was determined by real-time PCR on liver and lung tissue (Fig. 1C) . IL-6Ra protein was absent from liver and spleen lysates prepared from Il6ra 2/2 mice and present in WT (Il6ra +/+ ) and heterozygous (Il6ra +/2 ) mice (Fig. 1D) . Similarly, soluble IL-6Ra was abundant in Il6ra +/+ and Il6ra +/2 mice and undetectable in Il6ra 2/2 mice (Fig. 1E) . Although the presence of a truncated IL-6Ra protein in Il6ra 2/2 mice cannot be formally excluded, such a product is unlikely because of 1) the presence of an incomplete domain, 2) unpaired cysteine residues because of the deletion of the cytokine homology domain, and 3) the inability of a polyclonal Ab raised against the entire extracellular domain of IL-6Ra to recognize any product in null mice while detecting abundant product in WT mice. Il6ra 2/2 mice were normal in appearance and were born in the expected Mendelian ratio.
Il6ra
2/2 mice have a defective response to IL-6 IL-6 is critical for the acute-phase response to s.c. injected turpentine (43, 44) . To assess the response of Il6ra 2/2 mice, groups of mice were s.c. injected with turpentine. Hepatic production of the acute-phase reactants fibrinogen, haptoglobin, and SAA was markedly diminished or absent in Il6ra 2/2 mice, as assessed by real-time PCR ( Fig. 2A) and by ELISA for SAA (Fig. 2B) . Similar results were obtained in Il6 2/2 mice ( Fig. 2A, 2B ), as reported previously (43) . Thus, IL-6 signaling function is abrogated in Il6ra 2/2 mice in the context of generating an acute-phase response. IL-6 has been shown to be important in the progression of inflammatory responses from a neutrophil-dominant phase to a macrophage-dominant phase (21) . To determine whether this is also the case in Il6ra 2/2 mice, we created s.c. air pouches in mice and injected carrageenan as described previously (20) . Although the proportion of neutrophils and macrophages in the pouch fluid was not different between the groups 3 d after carrageenan administration, neutrophil resolution was impaired after 7 d (Fig. 2C) , and macrophage infiltration was delayed (Fig. 2D ) in both Il6 2/2 and Il6ra 2/2 mice. Given that IL-6Ra is believed to be the exclusive binding partner required to facilitate the interaction with the common IL-6 family receptor gp130, it was not surprising to find that deficiencies of either IL-6 or IL-6Ra induced the same phenotypic abnormalities compared with WT mice.
Hepatocyte production of IL-6Ra is critical for the acute-phase response but myeloid cells secrete most of the circulating IL-6Ra
IL-6Ra expression has been reported to be predominantly restricted to hepatocytes and immune cells. To elucidate the importance of each compartment in IL-6Ra-dependent processes, we generated mice with conditional deficiency of IL-6Ra in either hepatocytes or lysozyme M-expressing cells (macrophages and granulocytes) by crossing Il6ra fl/fl mice with mice expressing Cre recombinase under the control of the albumin (AlbCre) or lysozyme M (LysMCre) promoters, respectively. Significant reduction in IL-6Ra expression was observed in hepatocytes of AlbCre (Fig. 3B) . Interestingly, expression of soluble IL-6Ra in plasma was more dependent on immune cell secretion than on hepatic production, because LysMCre (Fig. 3C) . No differences were seen between WT and Il6ra fl/fl mice lacking Cre (data not shown). It is also noteworthy that macrophages, granulocytes, and hepatocytes together apparently account for almost all of the circulating IL6Ra in unchallenged mice, because the sum of the proportional 
/Il6ra
fl/fl (62.7% deficit) mice equaled 93.4% of the levels in WT mice. To determine the contributions of hepatocytes and immune cells to soluble IL-6Ra during inflammatory challenge, plasma and livers were collected from mice subjected to turpentine injection or cutaneous wounding. Despite increased expression of mRNA for IL-6ra in livers of WT mice subjected to acute-phase protein induction (Ref. 45 and our own unpublished data), no increase in the expression of soluble IL-6Ra was seen in mice challenged with turpentine or cutaneous wounding (Fig. 3C, 3D) .
We next compared acute-phase reactants in mice with conditional expression of IL-6Ra. As expected, generation of an acutephase response was completely muted in AlbCre +/+ /Il6ra fl/fl mice compared with WT or Il6ra fl/fl mice (Fig. 3E, 3F ). This is consistent with hepatocytes being the predominant cell type responsible for acute-phase responses. No significant difference was seen between LysMCre +/2 /Il6ra fl/fl mice and WT (Fig. 3E, 3F ) or LysMCre 2/2 /Il6ra fl/fl mice (data not shown). Despite in vitro reports that soluble IL-6Ra can enhance acute-phase protein expression in HepG2 cells (46) , no hepatic acute-phase response was detected in AlbCre +/+ /Il6ra fl/fl mice despite their having two-thirds of the WT expression of soluble IL-6Ra (Fig. 3C, 3D) . Apparently, membrane-bound IL-6Ra is essential for the hepatic acute-phase response to IL-6.
The deficit in wound healing is not as severe in Il6ra
2/2 mice as in Il6 2/2 mice It has previously been reported that wound healing is markedly delayed in Il6 2/2 mice (36, 37). We generated full-thickness small and large excision wounds to determine whether IL-6Ra 2/2 mice shared a similar phenotype. To our surprise, we found that Il6ra (Fig. 5A ). Differences in small biopsy punch wounds (4 mm in diameter) were subtle, as wounds healed rapidly (data not shown). However, large wounds of Il6 2/2 mice frequently became expanded beyond the boundaries of the original wound (Fig. 4A ), presumably by scratching or dragging of the wound with the mouse's limbs. This assumption was made because the extended edge of the wound was always on the caudal edge, which is more accessible to the legs of mice, and because this action was occasionally observed. Ulcers generated from this activity were seen in only one WT mouse (1 of 12 mice; 8%) with resolution within 24 h. Il6 2/2 mice all developed ulcers (12 of 12 mice, 100%), which had not healed at 8 d but were healing in some mice by the 11th day. Only 2 of 11 Il6ra 2/2 mice (18%)
developed ulcers adjacent to the wound area, and both were resolved within 24 h. Whether the formation of these ulcers was prompted by prolonged irritation from an open wound, psychological/stress-induced defects in Il6 2/2 mice (47), or phenotypic defects in wound contraction was not determined. Histological evaluation of the wound was performed to quantify differences in the multiple processes involved in successful wound healing. Re-epithelialization was markedly delayed in both Il6 2/2 and Il6ra 2/2 mice compared with WT mice in both large (Figs. 4B, 5C) and small wounds (Fig. 5D) . Separate experiments performed in mice with conditional expression of IL-6Ra indicated that hepatic expression of IL-6Ra was more important for re-epithelialization than that of myeloid cells (Fig. 5E ).
Delayed re-epithelialization in Il6ra 2/2 mice was an unexpected finding because macroscopic wound closure rates were similar to WT mice. Instead, wound contraction rates were similar in WT and Il6ra 2/2 mice but delayed in Il6 2/2 mice, accounting for the macroscopic observation of a smaller defect in Il6ra 2/2 mice than in Il6 2/2 mice (Fig. 5A , 5B). Deficits in the formation of granulation tissue were seen in both Il6 2/2 and Il6ra 2/2 mice but were more pronounced in Il6 2/2 mice. Deficits included delays in macrophage infiltration (Fig. 4C, 4D ), fibrin clearance (Fig. 4E) , and vascularization (Fig. 4F) . These deficits have previously been (Figs. 4, 5A , 5B). As differences were seen in wound healing between Il6 2/2 and Il6ra 2/2 mice, we wanted to determine whether IL-6 uses another receptor in the absence of IL-6Ra or whether the absence of the receptor itself may account for the improved wound-healing phenotype in Il6ra 2/2 mice. Some promiscuity exists in the IL-6 family of cytokines as high concentrations of CNTF or the IL-27 subunit p28 have been shown to induce a low level of signaling through IL-6Ra (1, 2, 49) , and differing phenotypes have been reported between receptor and ligand knockouts for CNTF. However, mammalian IL-6 is not known to have any activity independent of IL-6Ra. We hypothesized that if IL-6 could signal through another receptor, then wound healing would be expected to be delayed in mice with a combined deficit of IL-6 and IL-6Ra. Instead, closure of large excisional wounds in Il6 2/2 /Il6ra 2/2 mice occurred on a time frame most similar to Il6ra 2/2 mice, as did the formation of granulation tissue (Fig. 4) . Apparently, absence of the receptor is more important for rescuing wound healing in Il6ra
mice than is promiscuous IL-6 activity.
To confirm that the depletion of IL-6Ra improves wound contraction in Il6 2/2 mice, we treated mice with Abs specific for IL-6Ra and gp130. As expected, depletion of gp130 delayed wound contraction in WT mice (Fig. 5F, 5G ), consistent with its previously defined role in wound healing (50) but had no effect on Il6 2/2 mice (data not shown). However, although depletion of circulating IL-6Ra did not affect wound contraction in WT mice, it dramatically improved wound contraction in Il6 2/2 mice (Fig.   5F , 5G), similar to data obtained in mice with a combined genetic deficit of IL-6 and IL-6Ra. These data are consistent with the notion that IL-6Ra both facilitates wound healing in an IL-6-dependent fashion but also impairs wound healing in a manner that does not involve IL-6. To determine whether IL-27 p28 binding to IL-6Ra accounts for this negative effect of IL-6Ra in wound contraction, we treated mice with an Ab specific for murine p28.
The dose used was sufficient to prevent exogenous p28 from inducing primary murine macrophages from expressing IL-10 and suppressing IL-17 in vitro (data not shown wound contraction was seen with this treatment in either WT or Il6 2/2 mice (data not shown).
To identify a mechanism that could explain the timely wound healing observed in the absence of IL-6Ra regardless of the presence or absence of IL-6, we investigated signaling pathways known to be induced by IL-6Ra signaling. Stat3 phosphorylation was reduced to a similar extent in Il6 (Fig. 6B) . The difference in wound contraction rates was significantly delayed in Il6ra 2/2 mice treated with U0126 compared with vehicle control-treated mice but did not reach significance in WT mice (Fig. 6C ). These data suggest that, despite diminished Stat3 activation in Il6 2/2 and Il6ra 2/2 mice, enhanced ERK activation in Il6ra 2/2 mice may rescue wound contraction.
Discussion
In this paper, we provide the first report of mice with a complete deficiency of IL-6Ra and of mice with conditional deletion of IL-6Ra. Through studies in mice with conditional expression of IL-6Ra, we demonstrated that macrophages and granulocytes produce the majority of soluble circulating IL-6Ra (62.7%) in unchallenged and challenged mice and that hepatocytes produce most of the remainder (30.6%). The greater contribution by immune cells is consistent with immune cell-derived IL-6Ra being secreted and transported to distant inflammatory sites. Soluble IL-6Ra delivered to an inflammatory area allows IL-6 signaling through all cells present and, hence, a rapid response to injury or infection. Hepatic expression of IL-6Ra, however, appears to be more relevant to cell-type-specific rapid acute-phase responses specifically mediated by hepatocytes. However, it should be noted that differences in soluble IL-6Ra expression may exist in mice and humans, because mice are restricted to proteolytic cleavage and do not produce the differentially spliced form. It is of interest that the combined hepatic and granulocytic contribution of IL-6Ra apparently accounts for almost all (93.4%) of the soluble IL-6Ra expression in mice. It is possible that compensation from other compartments may occur in mice lacking IL-6Ra in particular cell types or that incomplete knockdown of IL-6Ra in macrophages and granulocytes with the lysozyme M promoter [95-99% efficiency in mature cells; 75-79% efficiency in bone marrow-derived cells (40)] accounts for residual IL-6Ra expression. However, the finding that macrophages, granulocytes, and hepatocytes are the major producers of soluble IL-6Ra is consistent with tissue expression studies (51). Our study did not address lymphocyte production of soluble IL-6Ra, but it is likely that these cells produce the remaining circulating IL6Ra in unchallenged mice and that their production increases during immune responses (52) .
On the basis of the similarities that we found between the phenotypes of Il6 2/2 and Il6ra 2/2 mice, it was somewhat surprising to find differences between these genotypes in woundhealing responses. Inflammation is an influential part of wound healing, and early granulation tissue contains many of the inflammatory cell types, cytokines, and angiogenic vessels typical of inflammation. Deficits in macrophage infiltration and subsequent fibrin clearance in Il6 2/2 mice were not typical in wounds of Il6ra 2/2 mice. The improved wound-healing phenotype in IL6Ra 2/2 mice indicates a divergence in functionality between IL-6 and IL-6Ra and possibly a compensatory mechanism in the absence of IL-6Ra. As mice with a combined deficiency of IL-6 and IL-6Ra demonstrated a wound-healing phenotype closely aligned with that of Il6ra 2/2 mice, it is likely that the absence of IL-6Ra played a greater role in rescuing the phenotype in Il6ra 2/2 mice than did IL-6 promiscuity. However, mice with both deficits did not heal as efficiently as Il6ra 2/2 mice.
Therefore, we cannot eliminate the possibility that IL-6 may also signal through a different receptor in these mice. Many interrelated processes involved in wound healing were improved in Il6ra efficiently, despite the delay in keratinocyte migration over the wound bed. Interestingly, experiments in mice with conditional expression of IL-6Ra indicated that hepatocyte IL-6Ra was more important in cutaneous wound re-epithelialization than that of macrophages and granulocytes. This finding is unexpected given that most circulating IL-6Ra comes from macrophages and granulocytes and because these cell types are numerous in healing wounds. Apparently, one or more of the numerous acute-phase reactants or growth factors produced by the liver in response to IL-6 contribute to reepithelialization.
In both knockout mice and Ab-depletion studies, we showed that depletion of IL-6Ra rescues wound healing in Il6 2/2 mice. No difference in Stat3 phosphorylation was seen between any of the wounds in the knockout mice, which in each case was less than the phosphorylated Stat3 observed in WT mice. Similarly, the lack of reepithelialization in both Il6 2/2 and Il6ra 2/2 mice, a Stat3-dependent process, argues against this mechanism alone accounting for the rescued wound healing observed in Il6ra 2/2 mice. Our data imply that IL-6Ra contributes positively to wound healing in an IL-6-and Stat3-dependent manner but potentially hinders wound contraction in an IL-6-independent fashion. This mechanism is unlikely to involve other IL-6 family ligands because they predominantly induce Jak/Stat signaling. However, because select ligands in the IL-6 family, specifically IL-27 p28 and CNTF, have been shown to mediate low-affinity binding to IL-6Ra in vitro (1, 2), we investigated the effect of blocking IL-27 p28 in vivo. We reasoned that if the interaction of this ligand with IL-6Ra accounted for the inhibitory effects of wound contraction by IL-6Ra, then blocking p28 with a specific Ab should rescue wound contraction in Il6 2/2 mice. Instead, no differences in wound contraction were seen in either WT or Il6 2/2 mice treated with Abs to p28. CNTF blocking experiments were not performed because CNTF production is restricted to glial and CNS cells, and CNTF does not possess a signal peptide for secretion. Instead, we investigated ERK activation as both a downstream mediator of IL-6Ra signaling (13, 53, 54) and as an important effector of wound contraction (55) . ERK phosphorylation was increased in wounds of Il6ra 2/2 mice but not Il6 2/2 mice, and blocking ERK activation with a MEK inhibitor delayed wound healing in Il6ra 2/2 mice. These data suggest that increased ERK activation increases wound contraction in Il6ra 2/2 mice but not in Il6 2/2 mice. We observed that topical application of the MEK inhibitor U0126 inhibited wound contraction to a greater extent in Il6ra 2/2 mice than in WT mice. Although it is tempting to speculate that wound healing in the absence of IL-6Ra may be more dependent on ERK activation than in WT mice, such a conclusion would be premature, because more studies are needed to determine the contributions of the MAPK or other signaling pathways and mechanisms to the healing process in Il6ra 2/2 mice.
In addition, it should be noted that the importance of such a mechanism remains to be determined, because it may prove to be specific to mice or may occur only in the context of the nonphysiological absence of IL-6Ra. Questions still remain regarding the mechanism by which deletion of IL-6Ra could lead to increased ERK activation, independently of IL-6 signaling. It could be that IL-6Ra plays a role in gp130 internalization and membrane expression, or a cytoplasmic phosphorylation site of IL-6Ra (56) may be involved in ERK suppression in the wound microenvironment. Sparse data suggest that gp130 and/or IL-6Ra interact with several adaptor proteins upstream of ERK activation, such as Grb1, Src homology region 2 domain-containing phosphatase 2, Vav, and Src family kinases (8, 53, 57-60). The depletion of IL-6Ra protein may deregulate the balance between these positive and negative effectors of the MAPK pathway, leading to increased ERK activation. In support of this idea, treatment of HepG2 cells with soluble IL-6Ra in the absence of IL-6 led to a complete inhibition of early growth response protein 1, a gene downstream of ERK activation (61) . Similarly, cross-talk between gp130 and/or IL-6Ra and the EGF family receptors has been reported in several tumor cell lines (62) (63) (64) (65) (66) and in primary mammary epithelial cells (67) . It is also possible that increased ERK activation in the absence of IL-6Ra is due to indirect effects on the expression or activity of other cytokines or on receptors other than gp130. It is not clear what the effect of IL-6Ra deficiency would have on these interactions. However, given the similarity between healing wounds and the tumor microenvironment and given that Abs against IL-6Ra are already in clinical usage in patients with rheumatic diseases, there is a strong rationale for better understanding this novel role for IL-6Ra in regulating ERK activation.
